PRATENSEIN manufacturers
- Pratensein
-
- $158.00
-
2026-07-15
- CAS:2284-31-3
- Purity: 99.90%
- Supply Ability: 10g
|
| | PRATENSEIN Basic information |
| Product Name: | PRATENSEIN | | Synonyms: | 5,7,3'-Trihydroxy-4'-methoxyisoflavone;5,7-Dihydroxy-3-(3-hydroxy-4-methoxyphenyl)-4H-1-benzopyran-4-one;PATCHOULI ALCOHOL (RG);4'-METHOXY-3',5,7-TRIHYDROXYISOFLAVONE;PRATENSEIN;PRALENREIN;OROBOL 4'-METHYL ETHER;Inhibitor,Nuclear factor-kappaB,Nuclear factor-κB,cognitive,inhibit,BDNF,synapse,Pratensein,damage,impairment,NF-κB,oxidative | | CAS: | 2284-31-3 | | MF: | C16H12O6 | | MW: | 300.26 | | EINECS: | | | Product Categories: | Iso-Flavones | | Mol File: | 2284-31-3.mol |  |
| | PRATENSEIN Chemical Properties |
| Melting point | 272-273° | | Boiling point | 576.7±50.0 °C(Predicted) | | density | 1.512±0.06 g/cm3(Predicted) | | pka | 6.45±0.20(Predicted) | | form | Solid | | color | White to off-white | | InChI | InChI=1S/C16H12O6/c1-21-13-3-2-8(4-11(13)18)10-7-22-14-6-9(17)5-12(19)15(14)16(10)20/h2-7,17-19H,1H3 | | InChIKey | FPIOBTBNRZPWJW-UHFFFAOYSA-N | | SMILES | C1OC2=CC(O)=CC(O)=C2C(=O)C=1C1=CC=C(OC)C(O)=C1 |
| | PRATENSEIN Usage And Synthesis |
| Uses | Pratensein, a flavonoid, ameliorates β-amyloid-induced cognitive impairment in rats via reducing oxidative damage and restoring synapse and BDNF levels[1]. | | Definition | ChEBI: A member of the class of 7-hydroxyisoflavones in which isoflavone is substituted by hydroxy groups at the 5, 7, and 3' positions, and by a methoxy group at the 4' position. | | in vivo | Pratensein significantly attenuates neuronal degeneration and apoptosis in hippocampus. The over-expression in IL-1β and TNF-α as well as the extensive astrogliosis and microgliosis in hippocampus induced by Aβ1-42 are significantly reduced following administration of Pratensein. Pratensein treatment significantly suppresses the activation of NF-κB in hippocampus. Pratensein is able to increase the levels of synaptophysin and brain-derived neurotrophic factor (BDNF)[1].
Pratensein (20 mg/kg; p.o.; once daily for 3 weeks) ameliorates learning and memory deficits in Aβ1-42 rat model of Alzheimer’s disease[1]. | Animal Model: | Male 10-week old Wistar rats[1] | | Dosage: | 20 mg/kg | | Administration: | P.o.; once daily for 3 weeks | | Result: | The spatial learning and memory ability of rats was improved.
|
| | References | [1] Liang C, et al. Pratensein ameliorates β-amyloid-induced cognitive impairment in rats via reducing oxidative damage and restoring synapse and BDNF levels. Neurosci Lett. 2015;592:48-53. DOI:10.1016/j.neulet.2015.03.003 |
| | PRATENSEIN Preparation Products And Raw materials |
|